Navigation Links
Archemix Announces Completion of Phase 1 Trial of ARC1779

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Archemix Corp., a biotechnology company focused on discovering and developing aptamers, announced the successful completion of a Phase 1 study of its novel aptamer therapeutic, ARC1779. ARC1779 is designed to selectively block the activation, adhesion and aggregation of platelets by inhibiting the binding of von Willebrand Factor (vWF) to the GPIb receptor on platelets. Activated vWF is scientifically recognized as the first stage of arterial thrombus formation and plays a significant role in the development of harmful blood clots. Archemix plans to develop ARC1779 as an anti-thrombotic drug for use in angioplasty and in a rare blood disorder that is mediated by vWF known as thrombotic thrombocytopenic purpura, or TTP.

Archemix plans to present a complete data set from this Phase 1 clinical trial within a peer-reviewed forum in 2007.

Based on the proof-of-mechanism data from this Phase 1 study, Archemix plans to commence a Phase 2 study of ARC1779 to evaluate the safety and efficacy of ARC1779 in acute coronary syndrome patients during the fourth quarter of 2007. Additionally, Archemix plans to initiate a Phase 1b study of ARC1779 in patients suffering from TTP in the fourth quarter of 2007. Approximately 3,000 new cases of TTP are diagnosed per year in the United States, but currently there is no approved drug therapy for the disease.

"We are very pleased to demonstrate ARC1779 can inhibit vWF activation and platelet function, which are both widely recognized as playing critical roles in clot formation which can critically impede blood flow to the heart," said Jim Gilbert, M.D., Chief Medical Officer, Archemix. "In Phase 2, we hope to show that using ARC1779 during angioplasty may improve myocardial perfusion by reducing blood clots in the coronary microcirculation while also providing effective anti-thrombotic treatment at the primary site of arte
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Archemix Announces Completion Phase Trial ARC1779
(Date:7/2/2015)... FORT LAUDERDALE, Fla. , July 2, 2015 ... & Co., is pleased to announce that its ... Inc. ("Insight Beverages") to Kerry Group plc (ISE: ... focused on taste and nutrition systems, as well ... food, beverage and pharmaceutical markets. Farlie Turner served ...
(Date:7/2/2015)... July 2, 2015 Releases of ... Aedes aegypti , , reduced the dengue ... Brazil by 95%, well below the modelled ... http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal PLOS Neglected Tropical ... Oxitec,s genetically engineered mosquitoes. The results showed that in ...
(Date:7/2/2015)... According to a new market research report " ... Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, Epilepsy, Ischemia, ... the global Neuromodulation Market is estimated at $3.65 Billion in ... at a CAGR of 11.2% during the forecast period. ... market data T ables and 32 ...
Breaking Medicine Technology:Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4
... Globus Medical, Inc., the largest,privately held spinal ... in motion preservation technology, today announced the completion ... study. The,SECURE(R)-C device is designed to mimic the ... pain and restore function as an alternative to ...
... Siemens Healthcare and,Laboratory Corporation of America(R) Holdings ... non-exclusive agreement to discuss future,possibilities to co-develop ... of,companion diagnostics, metabolic syndrome, oncology and diabetes. ... developing new tests that,could make the biggest ...
Cached Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4
(Date:7/4/2015)... ... , ... When a hacker gains access to someone’s email account, it can lead to all ... 1st, the FTC issued a scam alert about a social engineering scam which ... password reset instigated by the hacker. All they have to do is click for ...
(Date:7/3/2015)... Angeles, CA (PRWEB) , ... July 03, 2015 ... ... was opened for enrollment on July 2nd creating a buzz of media attention. ... has been published online by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people ...
(Date:7/3/2015)... ... ... Scientists at several top US cancer centers believe they now know why certain ... to read the complete story , just posted on the Surviving Mesothelioma website. ... New York University exposed mice with a mutation on the tumor suppressor gene called ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... to healthcare providers, has been retained to lead a national chief nursing ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing ... their existing Talcum Powder Cancer Lawsuit Center website. Just as the previous version did, ... news , offering timely lawsuit updates and ovarian cancer warning information. The site is ...
Breaking Medicine News(10 mins):Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3
... have identified childhood cancer survivors who are at ... due to the lifesaving bone marrow transplants they ... need for long-term monitoring and early intervention, particularly ... education, researchers said. Among the measures investigators recommend ...
... WASHINGTON, D.C. A scientifically-based tool developed by researchers ... women prevent pregnancy naturally, is now being used by ... An estimated twenty percent of women who wish ... know when they are fertile, according to the American ...
... ... the Socially Responsible (SRI) Bullion Fund Deploy Equity Long/Short Strategy with Apple ... companies with good bottom up fundamentals and sell closely related companies that ... to the overall markets. In this case, we go long an equally ...
... ... #1 brand in designer fashion shaping swimwear, has launched a line ... shaping construction. In launching this new collection, Miraclebody® announces a ... who can nominate themselves or others, this contest will honor and ...
... when green-eyed monster took over, study found , THURSDAY, April ... jealousy, according to a new study. , Researchers had heterosexual ... was told to look for pictures of landscapes amid rapidly ... upsetting image. , At the same time, her male partner ...
... ... ... Genesys Physician Hospital Organization (PHO) was faced with the challenging decision of building a ... careful cost analysis and evaluation of possible data centers, Genesys PHO choose colocation with ...
Cached Medicine News:Health News:Research findings underscore needed action to safeguard lungs of young cancer survivors 2Health News:Research findings underscore needed action to safeguard lungs of young cancer survivors 3Health News:Getting the bead on conception 2Health News:Getting the bead on conception 3Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 2Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 3Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 4Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 5Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 6Health News:Innovative Patent-pending Shapewear Technology Introduced for Jeans. 2Health News:Genesys PHO Outsources Data Center to Online Tech 2Health News:Genesys PHO Outsources Data Center to Online Tech 3Health News:Genesys PHO Outsources Data Center to Online Tech 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: